NCT05358379View on ClinicalTrials.gov

A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

April 14, 2022

Primary Completion Date

August 31, 2025

Study Completion Date

November 30, 2025

Conditions
Solid Tumor, Adult Lymphoma
Interventions
DRUG

CYC140

CYC140 is a highly selective, orally- and intravenously- available, ATP-competitive inhibitor of PLK1.

Trial Locations (5)

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

77030

RECRUITING

MD Anderson Cancer Center, Houston

91010

RECRUITING

City of Hope, Duarte

Unknown

RECRUITING

Seoul National University Hospital, Seoul

RECRUITING

Hospital Universitario Vall d'Hebron, Barcelona

Sponsors
All Listed Sponsors
lead

Cyclacel Pharmaceuticals, Inc.

INDUSTRY

NCT05358379 - A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma | Biotech Hunter | Biotech Hunter